BIA Separations in deal to expand virus purification offering

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/K_E_N)
(Image: Getty/K_E_N)

Related tags: BIA Separations, purification, Virus, Viral vector

In its latest deal, BIA Separations brings to market an elution method developed by the University of Zagreb, which helps preserve viruses’ integrity, infectivity, and potency.

Slovenia-based developer and manufacturer of large biomolecules, BIA Separations has reached a licensing agreement with the University of Zagreb for the commercialization of a technology used during the purification of viral vectors for gene therapy development.

Specifically, the technology regards an elution method that helps to better preserve the integrity, infectivity, and potency of viruses during immunoaffinity purification.

As explained by the company, immunoaffinity chromatography results in partial degradation of viral particles due to the low pH required for the elution. However, this method avoids degradation with the use of a concentrated solution of specifically selected amino acids and their salts.

Amino acids help maintain a neutral pH (6.0-8.0), leading to highly effective elution from immunoaffinity chromatographic, supporting intact and functional viruses for gene therapies.

A ‘one-stop-shop’ offering

The agreement will see the company add the elution method to its portfolio of services provided to biopharmaceutical R&D clients. Subsequently, research teams from both BIA Separations and the university will work collaboratively on follow-on technologies, aiming to further support the purification of viruses and viral vectors for research and clinical use.

Aleš Štrancar, CEO of BIA Separations, commented that the company aims to provide its customers with a ‘one-stop-shop’ for the manufacture of gene therapy vectors, vaccines, exosomes, DNA/RNA and other complex biopharmaceuticals.

He added that the partnership supports the plans for a fully integrated upstream and downstream processing with ‘robust’ in-process control, and noted that it is ‘one of a number’ collaborations currently in the company’s strategy.

This latest agreement follows the recent launch​ and expansion​ of the company’s set of Cornerstone services, designed to facilitate adeno-associated virus (AAV) production.

Related news

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars